Boundless Bio Secures $105 Million to Advance Oncology Therapies Against Extrachromosomal DNA

By McKenzie Carpenter Thursday, April 29, 2021

Boundless Bio, a precision oncology company, announced that the business has raised $105 million to aid in the advancement of next-generation oncology therapies that are directed to fight against extrachromosomal DNA (ecDNA).

3D illustration of a dividing cancer cell.

About Boundless Bio

Launched in 2019, Boundless Bio is a biopharmaceutical company that is working to develop an entirely new class of transformative, innovative oncology therapies to treat ecDNA in aggressive, intractable cancers.

The business states that ecDNA are small circles of DNA outside of the chromosome still confined within the nucleus. When DNA from cancer cells comes off of chromosomes, it rapidly replicates and is highly transcriptional, therefore enabling “numerous copies of cancer-causing genes and proteins, driving cancer cells to grow and allowing them to resist treatment.”

As a result, the company claims that people with cancers characterized by amplified oncogene ecDNA have a worse disease-free survival rate than those with cancers with non-circular amplifications or no amplifications at all. Oncogenes are genes that have the potential to cause cancer.

Based out of La Jolla, California, the business has the vision of creating “a world in which patients with ecDNA-driven cancer have access to powerful anti-cancer therapies that improve and prolong their lives.”

The cancer therapy and diagnostics company has an impressive team of scientific advisors from the University of California San Diego, Pennsylvania State University, Stanford University, The Scripps Research Institute, and The Jackson Laboratory.

Oversubscribed Series B

The company announced in a press release that Boundless Bio has raised $105 million in an oversubscribed Series B financing round co-led by RA Capital Management and Nextech Invest. Other top-tier syndicate funds also participated in this round. Crunchbase data indicates that with this new funding, Boundless Bio has raised a total of $151.4 million.

Zachary Hornby, president and CEO at Boundless Bio, stated in the announcement that the business developed Spyglass, a custom-built platform that has allowed the business to “interrogate ecDNA in cancer and reveal key therapeutically targetable liabilities in ecDNA-driven, gene amplified tumors.”

He added, “...This financing round and stellar investor syndicate reflects the investment community’s appreciation for the high unmet clinical need of patients with oncogene amplified cancers and the promise of our innovative approach to targeting ecDNA to improve and prolong the lives of these patients.”

With the new capital, the business plans to support the development of ecDNA-directed therapeutic programs and a companion diagnostic tool (ecDNA Harboring Oncogenes or ECHO) which is meant to identify patients with oncogene amplified cancers. Additionally, as a result of the financing, Jakob Loven, Ph.D., partner at Nextech Invest, will join the Board of Directors at the company.

The Worldwide Cancer Research Fund reported that there were 18 million cancer cases worldwide in 2018, with a prevalence that split almost halfway amongst men and women. In addition, The National Cancer Institute reported that in 2020, the United States (US) diagnosed an estimated 1.8 million new cases of cancer, with a death rate of nearly one-third of those cases.

Allied Market Research reported the global cancer therapeutics market was worth $98.9 billion in 2018 and is projected to reach $180.1 billion by 2026, growing at a CAGR of 7.7% from 2019 to 2026.

About the Author

Headshot for author McKenzie Carpenter

McKenzie Carpenter is a graduate of Central Michigan University with a B.A.A. in Integrative Public Relations and French. McKenzie has previously worked for small businesses and nonprofit organizations.

Related Articles